OtherClinical Investigations
The Placorhen Study: A Double-Blind, Placebo-Controlled, Randomized Radionuclide Study with 186Re-Etidronate in Hormone-Resistant Prostate Cancer Patients with Painful Bone Metastases
Shiuw H. Han, John M.H. de Klerk, Suzy Tan, Alfred D. van het Schip, Bert H. Derksen, Aalt van Dijk, Cas L.J.J. Kruitwagen, Geert H. Blijham, Peter P. van Rijk and Bernard A. Zonnenberg
Journal of Nuclear Medicine September 2002, 43 (9) 1150-1156;
Shiuw H. Han
John M.H. de Klerk
Suzy Tan
Alfred D. van het Schip
Bert H. Derksen
Aalt van Dijk
Cas L.J.J. Kruitwagen
Geert H. Blijham
Peter P. van Rijk
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
The Placorhen Study: A Double-Blind, Placebo-Controlled, Randomized Radionuclide Study with 186Re-Etidronate in Hormone-Resistant Prostate Cancer Patients with Painful Bone Metastases
Shiuw H. Han, John M.H. de Klerk, Suzy Tan, Alfred D. van het Schip, Bert H. Derksen, Aalt van Dijk, Cas L.J.J. Kruitwagen, Geert H. Blijham, Peter P. van Rijk, Bernard A. Zonnenberg
Journal of Nuclear Medicine Sep 2002, 43 (9) 1150-1156;
The Placorhen Study: A Double-Blind, Placebo-Controlled, Randomized Radionuclide Study with 186Re-Etidronate in Hormone-Resistant Prostate Cancer Patients with Painful Bone Metastases
Shiuw H. Han, John M.H. de Klerk, Suzy Tan, Alfred D. van het Schip, Bert H. Derksen, Aalt van Dijk, Cas L.J.J. Kruitwagen, Geert H. Blijham, Peter P. van Rijk, Bernard A. Zonnenberg
Journal of Nuclear Medicine Sep 2002, 43 (9) 1150-1156;
Related Articles
- No related articles found.
Cited By...
- Treatment with bone-seeking radionuclides for painful bone metastases in patients with lung cancer: a systematic review
- Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis
- High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the {alpha}-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?
- Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy
- Bone-Seeking Radionuclides For Therapy